C1 10190



SUB D2

§ 8. (Amended) A composition comprising 6ß, 7ß; 15ß, 16ß-dimethylene-3-oxo-17α -pregn-4-ene-21, 17-carbolactone of claim 4, a pharmaceutically acceptable carrier, and less then 0.2% by weight of said compound of the contaminants

C2



10191 and



wherein X is an anion of an acid which is effective to open said 6β, 7β-methylene group.. --

Please add the following new claims:

--10. A composition comprising

(a) 6β, 7β; 15β, 16β-dimethylene-3-oxo-17α-pregn-4-ene-21, 17-carbolactone of claim 1 made by a process comprising dehydrating a compound of Formula III,



III

which was made by oxidizing in the presence of a ruthenium salt a compound of Formula II,



II

which was made by catalytically hydrogenating a compound of Formula I



I

(b) a pharmaceutically acceptable carrier, and

(c) less then 0.2% by weight of said compound (a) of the byproducts of said preparation process which are



21

and



wherein X is an anion of an acid which is effective to open said 6β, 7β-methylene group.

11. A compound of claim 8, wherein in said process, said dehydrating is performed after said compound of Formula III is isolated from the medium in which it is prepared.

12. A compound of claim 6, wherein in said process, said dehydrating is performed after said compound of Formula III is isolated from the medium in which it is prepared.--